Figure 3.
Comparison between sGFAP (picograms/mL) values at baseline and after 6 and 12 months in EDA-3 and NEDA-3 patients after 2 years of Natalizumab. * (p = 0.01, p = 0.02), ns (non-significant).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.